cnbc.com / .cnbc-com-health-care

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.

Adtalem Global Education changed its name to Covista last week, a move the company says signals its ambitions in addressing the growing health-care worker gap.

Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.

The results signal steady progress in the health-care giant's aggressive turnaround plan under CEO David Joyner, who stepped into the role in late 2024.

A Florida state legislator sponsored the nation's first state-backed genetic screening program after his son died from a rare genetic disease.

The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal action.

Pfizer made one thing clear this week: It's officially back in the obesity race.